Loading clinical trials...

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER

NCT01468350•Acorda Therapeutics

View on ClinicalTrials.gov

Summary

A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•A diagnosis of CP
•No previous use of any dalfampridine formulation
•Ability to perform all the required study procedures. Subjects should be capable of fully extending and flexing both hands

Exclusion Criteria

•Presence of any progressive neurological disease
•Severe CP defined as the requirement to use a wheelchair at all times and a care taker for constant assistance in daily activities. This definition includes spastic quadriplegia
•Pregnant or breastfeeding

Locations (11)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Rancho Los Amigos National Rehabilitation Center

Downey, California, United States

UCLA/Orthopaedic Hospital Center for Cerebral Palsy

Los Angeles, California, United States

Rady Children's Hospital San Diego

San Diego, California, United States

Rehabilitation Institute of Chicago

Chicago, Illinois, United States

Kennedy Krieger Institute at Johns Hopkins University

Baltimore, Maryland, United States

Detroit Clinical Research Center

Farmington Hills, Michigan, United States

Gillette Children's Specialty Healthcare

Saint Paul, Minnesota, United States

University of Missouri at Columbia

Columbia, Missouri, United States

Cleveland Clinic

Cleveland, Ohio, United States

Key Dates

Start Date

December 1, 2011

Primary Completion Date

January 1, 2013

Completion Date

March 1, 2013

Last Updated

June 24, 2014

Enrollment

ACTUAL participants

Conditions

Cerebral Palsy (CP)

Interventions

dalfampridine-ER 10mg

DRUG

Placebo

OTHER

Intensive Rehabilitation Program for Upper Limb in Children and Adolescents With Cerebral Palsy

NCT07285837

Cerebral Palsy (CP)

View study

RECRUITING

Childhood Toxin Perception Survey

NCT07377201

Cerebral Palsy (CP)

View study

RECRUITING

Epidemiology of Sleep Disordered Breathing in Children and Young People With Cerebral Palsy

NCT06737302

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Inclusion Criteria

Exclusion Criteria

Intensive Rehabilitation Program for Upper Limb in Children and Adolescents With Cerebral Palsy

Childhood Toxin Perception Survey

Epidemiology of Sleep Disordered Breathing in Children and Young People With Cerebral Palsy

Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends

Bootle Blast: Pilot Randomized Controlled Trial

Rhythm Effect on Dance Learning in Typical Development Children and Children With Motor Disorders.